# Elliott P Vichinsky

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 405 papers | 21,505 citations | 69 h-index | 139 g-index |
| 432 ext. papers | 24,159 ext. citations | 5.8 avg, IF | 6.49 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 405 | Implications for the Metabolic Fate of Oral Glutamine Supplementation within Plasma and Erythrocytes of Patients with Sickle Cell Disease: A Pharmacokinetics Study.. *Complementary Therapies in Medicine*, **2022**, 102803 | 3.5 | 0 |
| 404 | Random Forest Clustering Identifies Three Subgroups of β-Thalassemia with Distinct Clinical Severity. *Thalassemia Reports*, **2022**, 12, 14-23 | 2 | 1 |
| 403 | Consensus statement for the perinatal management of patients with alpha thalassemia major. *Blood Advances*, **2021**, | 7.8 | 1 |
| 402 | Pituitary iron and factors predictive of fertility status in transfusion dependent thalassemia. *Haematologica*, **2021**, 106, 1740-1744 | 6.6 | 1 |
| 401 | Long-Term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia. *Blood*, **2021**, 138, 576-576 | 2.2 | 0 |
| 400 | An update on the US adult thalassaemia population: a report from the CDC thalassaemia treatment centres. *British Journal of Haematology*, **2021**, 196, 380 | 4.5 | 1 |
| 399 | Anterior Pituitary Volume in Patients with Transfusion Dependent Anemias: Volumetric Approaches and Relation to Pituitary MRI-R2. *Clinical Neuroradiology*, **2021**, 1 | 2.7 | |
| 398 | Voxelotor for the treatment of sickle cell disease. *Expert Review of Hematology*, **2021**, 14, 253-262 | 2.8 | 1 |
| 397 | Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia. *Haematologica*, **2021**, 106, 2489-2492 | 6.6 | 3 |
| 396 | Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Haematology,the*, **2021**, 8, e323-e333 | 14.6 | 14 |
| 395 | Stable to improved cardiac and pulmonary function in children with high-risk sickle cell disease following haploidentical stem cell transplantation. *Bone Marrow Transplantation*, **2021**, 56, 2221-2230 | 4.4 | 6 |
| 394 | Time to rethink haemoglobin threshold guidelines in sickle cell disease. *British Journal of Haematology*, **2021**, 195, 518-522 | 4.5 | 1 |
| 393 | A complication risk score to evaluate clinical severity of thalassaemia syndromes. *British Journal of Haematology*, **2021**, 192, 626-633 | 4.5 | 2 |
| 392 | Iron Deficiency: Implications Before Anemia. *Pediatrics in Review*, **2021**, 42, 11-20 | 1.1 | 2 |
| 391 | The transfusion management of beta thalassemia in the United States. *Transfusion*, **2021**, 61, 3027-3039 | 2.9 | 2 |
| 390 | Risk of mortality from anemia and iron overload in nontransfusion-dependent β-thalassemia. *American Journal of Hematology*, **2021**, | 7.1 | 1 |
| 389 | In Utero Stem Cell Transplantation in Patients with Alpha Thalassemia Major: Interim Results of a Phase 1 Clinical Trial. *Blood*, **2020**, 136, 1-1 | 2.2 | 1 |

| | | | |
|---|---|---|---|
| 388 | Three Distinct Groups of Phenotype Severity in Beta-Thalassemia. *Blood*, **2020**, 136, 15-16 | 2.2 | |
| 387 | Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis. *Blood*, **2020**, 136, 19-19 | 2.2 | 3 |
| 386 | Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study. *Blood*, **2020**, 136, 31-32 | 2.2 | 7 |
| 385 | Thalassemia Disorders in the Adolescent Female **2020**, 205-216 | | |
| 384 | Effect of Inhaled Cannabis for Pain in Adults With Sickle Cell Disease: A Randomized Clinical Trial. *JAMA Network Open*, **2020**, 3, e2010874 | 10.4 | 15 |
| 383 | Influence of sickle cell disease on susceptibility to HIV infection. *PLoS ONE*, **2020**, 15, e0218880 | 3.7 | 6 |
| 382 | Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report. *Annals of the American Thoracic Society*, **2019**, 16, e17-e32 | 4.7 | 15 |
| 381 | Evaluation of Mandible Fractures in Patients With Sickle Cell Anemia-A Nationwide Study. *Journal of Oral and Maxillofacial Surgery*, **2019**, 77, 1418-1422 | 1.8 | |
| 380 | Vincristine-induced anemia in hereditary spherocytosis. *Experimental Biology and Medicine*, **2019**, 244, 850-854 | 3.7 | 3 |
| 379 | Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study. *Lancet Neurology, The* , **2019**, 18, 631-642 | 24.1 | 61 |
| 378 | A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. *New England Journal of Medicine*, **2019**, 381, 509-519 | 59.2 | 200 |
| 377 | Mitapivat (AG-348), an Oral PK-R Activator, in Adults with Non-Transfusion Dependent Thalassemia: A Phase 2, Open-Label, Multicenter Study in Progress. *Blood*, **2019**, 134, 2249-2249 | 2.2 | 1 |
| 376 | Long-Term Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent Thalassemia in the Northstar (HGB-204) Study. *Blood*, **2019**, 134, 4628-4628 | 2.2 | 5 |
| 375 | Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study. *Blood*, **2019**, 134, 2313-2313 | 2.2 | 5 |
| 374 | Correlation of Voxelotor Exposure with Hemoglobin Response and Measures of Hemolysis in Patients from the HOPE Study. *Blood*, **2019**, 134, 1020-1020 | 2.2 | 2 |
| 373 | The prevention and management of alloimmunization in sickle cell disease: the benefit of extended phenotypic matching of red blood cells. *Immunohematology*, **2019**, 28, 20-23 | 0.4 | 20 |
| 372 | Trends in Iron Overload over Past Two Decades: Results from the Natural History of Iron Burden Study with the SQUID Biosusceptometer. *Blood*, **2019**, 134, 961-961 | 2.2 | |
| 371 | A Pilot Adult Sickle Cell Hematology Clinic in California's Inland Empire Improves Patient Outcome. *Blood*, **2019**, 134, 3470-3470 | 2.2 | |

| | | | |
|---|---|---|---|
| 370 | Development of a Severity Score System for Thalassemia Syndromes. *Blood*, **2019**, 134, 2225-2225 | 2.2 | 0 |
| 369 | Fertility and Pregnancy in Women with Transfusion-Dependent Thalassemia. *Hematology/Oncology Clinics of North America*, **2018**, 32, 297-315 | 3.1 | 14 |
| 368 | Epidemiologic and clinical characteristics of nontransfusion-dependent thalassemia in the United States. *Pediatric Blood and Cancer*, **2018**, 65, e27067 | 3 | 11 |
| 367 | Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia. *New England Journal of Medicine*, **2018**, 378, 1479-1493 | 59.2 | 347 |
| 366 | Sickle cell disease. *Nature Reviews Disease Primers*, **2018**, 4, 18010 | 51.1 | 373 |
| 365 | Variability of homozygous sickle cell disease: The role of alpha and beta globin chain variation and other factors. *Blood Cells, Molecules, and Diseases*, **2018**, 70, 66-77 | 2.1 | 20 |
| 364 | A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. *New England Journal of Medicine*, **2018**, 379, 226-235 | 59.2 | 212 |
| 363 | Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia Following Completion of the Northstar HGB-204 Study. *Blood*, **2018**, 132, 167-167 | 2.2 | 2 |
| 362 | Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease. *Blood*, **2018**, 132, 505-505 | 2.2 | 2 |
| 361 | Significantly Improved Long Term Health Related Quality of Life (HRQL) and Neurocognition Following Familial Haploidentical Stem Cell Transplantation (HISCT) Utilizing CD34 Enrichment and Mononuclear (CD3) Addback in High Risk Patients with Sickle Cell Disease (SCD). *Blood*, **2018**, 132, 162-162 | 2.2 | 0 |
| 360 | Transfusion practices and complications in thalassemia. *Transfusion*, **2018**, 58, 2826-2835 | 2.9 | 12 |
| 359 | Emergency department utilization by Californians with sickle cell disease, 2005-2014. *Pediatric Blood and Cancer*, **2017**, 64, e26390 | 3 | 27 |
| 358 | Lifespan care in SCD: Whom to transition, the patients or the health care system?. *American Journal of Hematology*, **2017**, 92, 487-489 | 7.1 | 7 |
| 357 | Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial. *British Journal of Haematology*, **2017**, 177, 620-629 | 4.5 | 39 |
| 356 | Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5-year observational study (ENTRUST). *Pediatric Blood and Cancer*, **2017**, 64, e26507 | 3 | 12 |
| 355 | Dietary nonheme iron is equally bioavailable from ferritin or ferrous sulfate in thalassemia intermedia. *Pediatric Hematology and Oncology*, **2017**, 34, 455-467 | 1.7 | 2 |
| 354 | Encephaloduroarteriosynangiosis (EDAS) in young patients with cerebrovascular complications of sickle cell disease: Single-institution experience. *Pediatric Hematology and Oncology*, **2017**, 34, 100-106 | 1.7 | 5 |
| 353 | Chronic organ failure in adult sickle cell disease. *Hematology American Society of Hematology Education Program*, **2017**, 2017, 435-439 | 3.1 | 21 |

| | | | |
|---|---|---|---|
| 352 | Systemic Biomarkers Show Elevated Oxidative Stress and Chronic Inflammation in Two Disorders of Neurodegeneration with Brain Iron Accumulation (NBIA). *Blood*, **2017**, 130, 943-943 | 2.2 | |
| 351 | Favorable outcomes after in utero transfusion in fetuses with alpha thalassemia major: a case series and review of the literature. *Prenatal Diagnosis*, **2016**, 36, 1242-1249 | 3.2 | 27 |
| 350 | Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management. *Current Medical Research and Opinion*, **2016**, 32, 191-204 | 2.5 | 38 |
| 349 | Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia: Update from the Northstar Hgb-204 Phase 1/2 Clinical Study. *Blood*, **2016**, 128, 1175-1175 | 2.2 | 13 |
| 348 | Sickle Cell Disease: Management of Complications **2016**, 75-87 | | |
| 347 | Threshold Ferritin Values to Predict Control of Liver Iron Burden in Thalassemia. *Blood*, **2016**, 128, 4824-4824 | 2.2 | |
| 346 | Long-Term Therapy with Deferasirox in Young Pediatric Patients with Transfusional Hemosiderosis Completing up to 5 Years of Treatment in the Observational E.N.T.R.U.S.T. Study. *Blood*, **2016**, 128, 2470-2470 | 2.2 | |
| 345 | Episodic Patterns of High Emergency Department Utilization Among Sickle Cell Disease Patients. *Blood*, **2016**, 128, 316-316 | 2.2 | |
| 344 | Sickle cell anemia, thalassemia, and congenital hemolytic anemias **2016**, 126-143 | | 5 |
| 343 | Is the medical home for adult patients with sickle cell disease a reality or an illusion?. *Hemoglobin*, **2015**, 39, 130-3 | 0.6 | 3 |
| 342 | Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. *British Journal of Haematology*, **2015**, 169, 887-98 | 4.5 | 16 |
| 341 | Fertility in transfusion-dependent thalassemia men: effects of iron burden on the reproductive axis. *American Journal of Hematology*, **2015**, 90, E190-2 | 7.1 | 16 |
| 340 | Update of Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex-Vivo with a Lentiviral Beta AT87Q-Globin Vector (LentiGlobin BB305 Drug Product). *Blood*, **2015**, 126, 201-201 | 2.2 | 15 |
| 339 | Epidemiologic and Clinical Characteristics of Thalassemia (Thal) Intermedia (TI) in the United States. *Blood*, **2015**, 126, 3279-3279 | 2.2 | 1 |
| 338 | The Effects of Glutamine Supplementation on Markers of Autophagy and Apoptosis in Peripheral Blood Mononuclear Cells from Patients with Sickle Cell Disease. *Blood*, **2015**, 126, 3412-3412 | 2.2 | |
| 337 | NKTT120 Safely Depletes iNKT Cells in Stable Adult Sickle Cell Patients in a Phase 1 Trial. *Blood*, **2015**, 126, 2178-2178 | 2.2 | |
| 336 | Iron Level and Monocyte Morphology Predict TLR4 Expression and Reactive Oxygen Species Production Which Influences Chronic Inflammation in β-Thalassemia. *Blood*, **2015**, 126, 950-950 | 2.2 | |
| 335 | In utero hematopoietic cell transplantation for hemoglobinopathies. *Frontiers in Pharmacology*, **2014**, 5, 278 | 5.6 | 20 |

| | | | |
|---|---|---|---|
| 334 | Elevated tricuspid regurgitant jet velocity in subgroups of thalassemia patients: insight into pathophysiology and the effect of splenectomy. *Annals of Hematology*, **2014**, 93, 1139-48 | 3 | 13 |
| 333 | Response to "efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up " Haematologica 2014;99(2):e17-18. *Haematologica*, **2014**, 99, e19 | 6.6 | |
| 332 | Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients. *British Journal of Haematology*, **2014**, 167, 692-6 | 4.5 | 42 |
| 331 | Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). *Transfusion*, **2014**, 54, 972-81; quiz 971 | 2.9 | 69 |
| 330 | Validation and reliability of a disease-specific quality of life measure (the TranQol) in adults and children with thalassaemia major. *British Journal of Haematology*, **2014**, 164, 431-7 | 4.5 | 19 |
| 329 | Renal medullary carcinoma in an adolescent with sickle cell anemia. *Pediatric Blood and Cancer*, **2014**, 61, 567 | 3 | 11 |
| 328 | Population based surveillance in sickle cell disease: methods, findings and implications from the California registry and surveillance system in hemoglobinopathies project (RuSH). *Pediatric Blood and Cancer*, **2014**, 61, 2271-6 | 3 | 28 |
| 327 | NKTT120 Reduces iNKT Cells without Dose Limiting Toxicity in Stable Adult Sickle Cell Patients in a Phase 1 Trial. *Blood*, **2014**, 124, 2718-2718 | 2.2 | 2 |
| 326 | Comparison of Clinical Outcomes Between Adult and Pediatric Patients (pts) with Sickle Cell Disease (SCD): 3-Year (y) Follow-up in a Prospective, Longitudinal, Noninterventional Registry Trial. *Blood*, **2014**, 124, 4890-4890 | 2.2 | 1 |
| 325 | Pituitary Iron and Volume Are Affecting Hormones and Reproductive Potential. *Blood*, **2014**, 124, 4048-4048 | 2.2 | |
| 324 | Impact of Immigration and Migration on Thalassemia Surveillance in California, 2004-2008. *Blood*, **2014**, 124, 4855-4855 | 2.2 | 1 |
| 323 | Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. *American Journal of Hematology*, **2013**, 88, 1068-73 | 7.1 | 24 |
| 322 | Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. *Journal of Cardiovascular Magnetic Resonance*, **2013**, 15, 38 | 6.9 | 35 |
| 321 | Pregnancy outcomes in women with thalassemia in North America and the United Kingdom. *American Journal of Hematology*, **2013**, 88, 771-3 | 7.1 | 20 |
| 320 | Combined chelation therapy with deferasirox and deferoxamine in thalassemia. *Blood Cells, Molecules, and Diseases*, **2013**, 50, 99-104 | 2.1 | 55 |
| 319 | Non-transfusion-dependent thalassemias. *Haematologica*, **2013**, 98, 833-44 | 6.6 | 179 |
| 318 | Increased leucocyte apoptosis in transfused □thalassaemia patients. *British Journal of Haematology*, **2013**, 160, 399-403 | 4.5 | 5 |
| 317 | Application of multiplex ligation-dependent probe amplification to screen for □globin cluster deletions: detection of two novel deletions in a multi ethnic population. *Hemoglobin*, **2013**, 37, 241-56 | 0.6 | 8 |

| | | | |
|---|---|---|---|
| 316 | Treatment of classic pantothenate kinase-associated neurodegeneration with deferiprone and intrathecal baclofen. *American Journal of Physical Medicine and Rehabilitation*, **2013**, 92, 728-33 | 2.6 | 22 |
| 315 | Zinc supplementation improves bone density in patients with thalassemia: a double-blind, randomized, placebo-controlled trial. *American Journal of Clinical Nutrition*, **2013**, 98, 960-71 | 7 | 31 |
| 314 | Clinical manifestations of β-thalassemia. *Cold Spring Harbor Perspectives in Medicine*, **2013**, 3, a011742 | 5.4 | 55 |
| 313 | Pain in thalassaemia: the effects of age on pain frequency and severity. *British Journal of Haematology*, **2013**, 160, 680-7 | 4.5 | 24 |
| 312 | Pain over time and its effects on life in thalassemia. *American Journal of Hematology*, **2013**, 88, 939-43 | 7.1 | 11 |
| 311 | The palatability and tolerability of deferasirox taken with different beverages or foods. *Pediatric Blood and Cancer*, **2013**, 60, 1507-12 | 3 | 18 |
| 310 | Human T cell lymphotropic virus type 1 infection among U.S. thalassemia patients. *AIDS Research and Human Retroviruses*, **2013**, 29, 1006-9 | 1.6 | 4 |
| 309 | A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. *Haematologica*, **2013**, 98, 1375-82 | 6.6 | 100 |
| 308 | Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. *Haematologica*, **2013**, 98, 1359-67 | 6.6 | 35 |
| 307 | Inflammatory and Vitamin Bio-Markers Of Iron Trafficking and Distribution In Transfusional Overload: Insights From Comparing Diamond Blackfan Anemia With Sickle Cell Disease and Thalassemia (MCSIO PILOT Study). *Blood*, **2013**, 122, 1014-1014 | 2.2 | |
| 306 | Association Of Cardiac Iron By T2* With Innate Immune Markers In Transfusion-Dependent Thalassemia Patients Undergoing Combined Chelation Therapy. *Blood*, **2013**, 122, 3450-3450 | 2.2 | |
| 305 | Citrate Synthase Activity Is Increased In Children With Sickle Cell Disease (SCD) On Hydroxyurea (HU) Therapy. *Blood*, **2013**, 122, 4690-4690 | 2.2 | |
| 304 | Abnormal Reproductive Measures and Seminal Plasma Findings in Men With Thalassemia Major (TM) and Iron Overload. *Blood*, **2013**, 122, 4707-4707 | 2.2 | |
| 303 | Clinical Outcomes For Patients With Sickle Cell Disease: 24-Month Follow-Up In An Ongoing 3-Year, Prospective, Non-Interventional Registry Trial. *Blood*, **2013**, 122, 988-988 | 2.2 | 2 |
| 302 | Lower alloimmunization rates in pediatric sickle cell patients on chronic erythrocytapheresis compared to chronic simple transfusions. *Transfusion*, **2012**, 52, 2671-6 | 2.9 | 53 |
| 301 | Safety of deferasirox in sickle cell disease patients with co-existing liver impairment □ response to Sinakos et□al. *British Journal of Haematology*, **2012**, 157, 506-507 | 4.5 | |
| 300 | Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. *Blood*, **2012**, 119, 2746-53 | 2.2 | 63 |
| 299 | Advances in the treatment of alpha-thalassemia. *Blood Reviews*, **2012**, 26 Suppl 1, S31-4 | 11.1 | 38 |

| | | | |
|---|---|---|---|
| 298 | Identification of three novel Hb F variants: Hb F-Hayward [G(1)(NA1)Gly->Asp, GGT>GAT], Hb F-Chori-I [A16(A13)Gly->Asp, GGC>GAC] and Hb F-Chori-II [A29(B11)Gly->Glu, GGA>GAA]. *Hemoglobin*, **2012**, 36, 305-9 | 0.6 | 1 |
| 297 | Inadequate dietary intake in patients with thalassemia. *Journal of the Academy of Nutrition and Dietetics*, **2012**, 112, 980-90 | 3.9 | 31 |
| 296 | The effect of whole body vibration therapy on bone density in patients with thalassemia: a pilot study. *American Journal of Hematology*, **2012**, 87, E76-9 | 7.1 | 7 |
| 295 | A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease. *American Journal of Hematology*, **2012**, 87, 1017-21 | 7.1 | 28 |
| 294 | A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. *American Journal of Hematology*, **2012**, 87, 536-9 | 7.1 | 61 |
| 293 | Emerging 'A' therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine. *Hematology American Society of Hematology Education Program*, **2012**, 2012, 271-5 | 3.1 | 10 |
| 292 | Emerging A therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine. *Hematology American Society of Hematology Education Program*, **2012**, 2012, 271-275 | 3.1 | 21 |
| 291 | Sildenafil Therapy in Patients with Thalassemia and an Elevated Tricuspid Regurgitant Jet Velocity (TRV) On Doppler Echocardiography At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network. *Blood*, **2012**, 120, 1023-1023 | 2.2 | 1 |
| 290 | Innate Immune Cell Expression of Pattern Recognition Receptors From Thalassemia Patients During Intensive Combination Chelation Therapy. *Blood*, **2012**, 120, 1025-1025 | 2.2 | 1 |
| 289 | Quality Improvement Goals for Sickle Cell Disease Pain Management in an Urban Pediatric Emergency Department: We Can Do Better!.. *Blood*, **2012**, 120, 2101-2101 | 2.2 | 1 |
| 288 | Interim Safety and Effectiveness Results From a 5-Year Observational Study of Deferasirox in Pediatric Patients Aged 2 *Blood*, **2012**, 120, 2125-2125 | 2.2 | 1 |
| 287 | Renal Medullary Carcinoma in an Adolescent with Homozygous Hemoglobin SS. *Blood*, **2012**, 120, 4774-4774 | 2.2 | |
| 286 | Cardiopulmonary and Laboratory Profiling of Patients with Thalassemia At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network.. *Blood*, **2012**, 120, 2122-2122 | 2.2 | |
| 285 | Iron Trafficking and Distribution in Transfusional Overload: Insights From Comparing Diamond Blackfan Anemia with Sickle Cell Disease and Thalassemia. *Blood*, **2012**, 120, 995-995 | 2.2 | 1 |
| 284 | 12-Month Follow-up for Patients with Sickle Cell Disease in an Ongoing 3-Year, Prospective, Non-Interventional Registry Trial. *Blood*, **2012**, 120, 1010-1010 | 2.2 | |
| 283 | Tricuspid Regurgitant Jet Velocity (TRV), Biomarkers of Hemolysis, and Impact of Oxygen Therapy in Children with Sickle Cell Disease (SCD) and Vaso-Occlusive Pain Episodes (VOE). *Blood*, **2012**, 120, 4752-4752 | 2.2 | |
| 282 | Transfusion and chelation practices in sickle cell disease: a regional perspective. *Pediatric Hematology and Oncology*, **2011**, 28, 124-33 | 1.7 | 19 |
| 281 | Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover. *Bone*, **2011**, 48, 1305-12 | 4.7 | 32 |

| | | | |
|---|---|---|---|
| 280 | Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. *Blood*, **2011**, 118, 3794-802 | 2.2 | 49 |
| 279 | A pilot study of subcutaneous decitabine in thalassemia intermedia. *Blood*, **2011**, 118, 2708-11 | 2.2 | 65 |
| 278 | Reproductive capacity in iron overloaded women with thalassemia major. *Blood*, **2011**, 118, 2878-81 | 2.2 | 43 |
| 277 | A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. *Haematologica*, **2011**, 96, 521-5 | 6.6 | 35 |
| 276 | A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. *British Journal of Haematology*, **2011**, 153, 655-63 | 4.5 | 58 |
| 275 | Red cell alloimmunization in a diverse population of transfused patients with thalassaemia. *British Journal of Haematology*, **2011**, 153, 121-8 | 4.5 | 84 |
| 274 | Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. *British Journal of Haematology*, **2011**, 154, 281-4 | 4.5 | 12 |
| 273 | Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. *British Journal of Haematology*, **2011**, 154, 387-97 | 4.5 | 59 |
| 272 | Novel influenza A (H1N1) viral infection in pediatric patients with sickle-cell disease. *Pediatric Blood and Cancer*, **2011**, 56, 95-8 | 3 | 10 |
| 271 | The mediating effects of family functioning on psychosocial outcomes in healthy siblings of children with sickle cell disease. *Pediatric Blood and Cancer*, **2011**, 57, 1055-61 | 3 | 17 |
| 270 | Iron chelation adherence to deferoxamine and deferasirox in thalassemia. *American Journal of Hematology*, **2011**, 86, 433-6 | 7.1 | 46 |
| 269 | Heterogeneity of hemoglobin H disease in childhood. *New England Journal of Medicine*, **2011**, 364, 710-8 | 59.2 | 108 |
| 268 | Approaches to transfusion therapy and iron overload in patients with sickle cell disease: results of an international survey. *Pediatric Hematology and Oncology*, **2011**, 28, 37-42 | 1.7 | 15 |
| 267 | Baseline Characteristics of Patients with Sickle Cell Disease in An Ongoing 5-Year, Prospective, Noninterventional Registry Trial. *Blood*, **2011**, 118, 1060-1060 | 2.2 | 3 |
| 266 | A Randomized Phase II Study Evaluating the Efficacy and Safety of Deferasirox Versus Deferoxamine in Patients with Sickle Cell Disease (SCD): 2-Year Results Including Pharmacokinetics (PK) and Safety of Deferasirox with Concomitant Hydroxyurea Therapy. *Blood*, **2011**, 118, 1082-1082 | 2.2 | 3 |
| 265 | Transfusion Complications in Thalassemia: A Report From the Centers for Disease Control and Prevention (CDC). *Blood*, **2011**, 118, 340-340 | 2.2 | 1 |
| 264 | Hb E/beta-thalassaemia: a common & clinically diverse disorder. *Indian Journal of Medical Research*, **2011**, 134, 522-31 | 2.9 | 36 |
| 263 | Hemoglobinopathies **2011**, 1662-1677.e1 | | 2 |

| | | | |
|---|---|---|---|
| 262 | Safety, Tolerability and Dose Response of FBS0701, a Novel Iron Chelator for Treatment of Transfusional Iron Overload: Results of a 24-Week Multicenter, International Phase 2 Study. *Blood*, **2011**, 118, 690-690 | 2.2 | |
| 261 | Effect of Short-Term Simvastatin Treatment on Endothelial Adhesion Molecules in Sickle Cell Disease: A Pilot Study. *Blood*, **2011**, 118, 1070-1070 | 2.2 | |
| 260 | Mental Health Symptoms, Quality of Life and Barriers to Accessing Health Care in Sickle Cell Disease. *Blood*, **2011**, 118, 337-337 | 2.2 | |
| 259 | Oxidative Stress and Reproductive Capacity in Iron Overload Thalassemia Major Women. *Blood*, **2011**, 118, 2155-2155 | 2.2 | |
| 258 | Evaluation of Moyamoya Disease in Sickle Cell Anemia Patients After Encephaloduroarteriosynangiosis. *Blood*, **2011**, 118, 1059-1059 | 2.2 | |
| 257 | Complexity of alpha thalassemia: growing health problem with new approaches to screening, diagnosis, and therapy. *Annals of the New York Academy of Sciences*, **2010**, 1202, 180-7 | 6.5 | 45 |
| 256 | Pulmonary hypertension in thalassemia. *Annals of the New York Academy of Sciences*, **2010**, 1202, 205-13 | 6.5 | 50 |
| 255 | Fertility potential in thalassemia major women: current findings and future diagnostic tools. *Annals of the New York Academy of Sciences*, **2010**, 1202, 226-30 | 6.5 | 13 |
| 254 | Preface to Cooley's Anemia: Ninth Symposium. *Annals of the New York Academy of Sciences*, **2010**, 1202, ix-x | 6.5 | 1 |
| 253 | Elevated exhaled carbon monoxide concentration in hemoglobinopathies and its relation to red blood cell transfusion therapy. *Pediatric Hematology and Oncology*, **2010**, 27, 112-21 | 1.7 | 10 |
| 252 | Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. *JAMA - Journal of the American Medical Association*, **2010**, 303, 1823-31 | 27.4 | 187 |
| 251 | Severe sickle cell disease--pathophysiology and therapy. *Biology of Blood and Marrow Transplantation*, **2010**, 16, S64-7 | 4.7 | 25 |
| 250 | HbE/β-thalassemia: basis of marked clinical diversity. *Hematology/Oncology Clinics of North America*, **2010**, 24, 1055-70 | 3.1 | 21 |
| 249 | Chart Card: feasibility of a tool for improving emergency department care in sickle cell disease. *Journal of the National Medical Association*, **2010**, 102, 1017-23 | 2.3 | 7 |
| 248 | Pulmonary hypertension and NO in sickle cell. *Blood*, **2010**, 116, 852-4 | 2.2 | 51 |
| 247 | Relationship between chronic transfusion therapy and body composition in subjects with thalassemia. *Journal of Pediatrics*, **2010**, 157, 641-7, 647.e1-2 | 3.6 | 20 |
| 246 | Assessment of cardiac iron by MRI susceptometry and R2* in patients with thalassemia. *Magnetic Resonance Imaging*, **2010**, 28, 363-71 | 3.3 | 13 |
| 245 | Hemoglobin Hakkari: an autosomal dominant form of beta thalassemia with inclusion bodies arising from de novo mutation in exon 2 of beta globin gene. *Pediatric Blood and Cancer*, **2010**, 54, 332-5 | 3 | 6 |

| | | | |
|---|---|---|---|
| 244 | Low dose, oral epsilon aminocaproic acid for renal papillary necrosis and massive hemorrhage in hemoglobin SC disease. *Pediatric Blood and Cancer*, **2010**, 54, 148-50 | 3 | 4 |
| 243 | Education and employment status of children and adults with thalassemia in North America. *Pediatric Blood and Cancer*, **2010**, 55, 678-83 | 3 | 9 |
| 242 | A Randomized Trial of the Safety and Benefit of Transfusion Vs. Standard Care In the Prevention of Sickle Cell-Related Complications In Adults: a Preliminary Report From the Phase II NHLBI Comprehensive Sickle Cell Centers (CSCC) Study of Neuropsychological Dysfunction and Neuroimaging Abnormalities In Neurologically Intact Adult Patients with Sickle Cell Disease. *Blood*, [illegible] | 2.2 | 3 |
| 241 | Combined Chelation Therapy with Deferasirox and Deferoxamine In Transfusion-Dependent Thalassemia. *Blood*, **2010**, 116, 4269-4269 | 2.2 | 2 |
| 240 | Long-Term Safety and Efficacy of Deferasirox (Exjade ) In Transfused Patients with Sickle Cell Disease Treated for up to 5 Years. *Blood*, **2010**, 116, 845-845 | 2.2 | 1 |
| 239 | Pulmonary hypertension in hemolytic anemias. *F1000 Medicine Reports*, **2010**, 2, | | 13 |
| 238 | A Phase 1B Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FBS0701, a Novel Oral Iron Chelator for the Treatment of Chronic Iron Overload. *Blood*, **2010**, 116, 2057-2057 | 2.2 | |
| 237 | Emergency Room Utilization by California Sickle Cell Patients During Pediatric to Adult Care Transition. *Blood*, **2010**, 116, 254-254 | 2.2 | |
| 236 | The Palatability and Tolerability of Deferasirox (Exjade ) Taken with Meals, Different Liquids, or Crushed and Added to Food. *Blood*, **2010**, 116, 5155-5155 | 2.2 | |
| 235 | A New Method of Hip Coring Decompression for the Treatment of Femoral Avascular Necrosis In Sickle Cell Disease: Perioperative Safety and Preliminary Efficacy Data. *Blood*, **2010**, 116, 264-264 | 2.2 | |
| 234 | The Effect of Thalassemia and Other RBC Hemolytic Disorders and Splenectomy on the Frequency of Pulmonary Hypertension. *Blood*, **2010**, 116, 2077-2077 | 2.2 | |
| 233 | Phenomenon of Pain In Thalassemia: A Prospective Analysis by the Thalassemia Clinical Research Network (TCRN). *Blood*, **2010**, 116, 256-256 | 2.2 | |
| 232 | A Pilot Study of Epigenetic-Differentiation Therapy with Decitabine to Treat Thalassemia Intermedia. *Blood*, **2010**, 116, 2078-2078 | 2.2 | |
| 231 | Longitudinal Follow-up From Newborn Screening Reveals Deletional Hemoglobin H Disease and Hemoglobin H Constant Spring Disease Are Distinct Thalassemia Syndromes. *Blood*, **2010**, 116, 4260-4260 | 2.2 | |
| 230 | HLA type and risk of alloimmunization in sickle cell disease. *American Journal of Hematology*, **2009**, 84, 462-4 | 7.1 | 41 |
| 229 | Hemoglobin H-constant spring in North America: an alpha thalassemia with frequent complications. *American Journal of Hematology*, **2009**, 84, 759-61 | 7.1 | 14 |
| 228 | Newborn screening for hemoglobinopathies in California. *Pediatric Blood and Cancer*, **2009**, 52, 486-90 | 3 | 122 |
| 227 | Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. *British Journal of Haematology*, **2009**, 146, 546-56 | 4.5 | 128 |

| | | | |
|---|---|---|---|
| 226 | Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. *British Journal of Haematology*, **2009**, 147, 752-9 | 4.5 | 94 |
| 225 | Bone disease in thalassemia: a frequent and still unresolved problem. *Journal of Bone and Mineral Research*, **2009**, 24, 543-57 | 6.3 | 153 |
| 224 | Iron metabolism and iron chelation in sickle cell disease. *Acta Haematologica*, **2009**, 122, 174-83 | 2.7 | 37 |
| 223 | Alpha thalassemia major--new mutations, intrauterine management, and outcomes. *Hematology American Society of Hematology Education Program*, **2009**, 35-41 | 3.1 | 51 |
| 222 | Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. *Blood*, **2009**, 114, 4632-8 | 2.2 | 90 |
| 221 | Pulmonary Hypertension in Thalassemia Assessed by Echocardiography: A Report From Baseline Data of the Thalassemia Clinical Research Network Longitudinal Cohort Study.. *Blood*, **2009**, 114, 2016-2016 | 2.2 | 2 |
| 220 | Safety of Combined Chelation Therapy with Deferasirox and Deferoxamine in Transfusion-Dependent Thalassemia.. *Blood*, **2009**, 114, 2021-2021 | 2.2 | 4 |
| 219 | The Effect of Short-Term Simvastatin On Markers of Vascular Dysfunction in Patients with Sickle Cell Disease (SCD).. *Blood*, **2009**, 114, 260-260 | 2.2 | 1 |
| 218 | Chelation Choices and Iron Burden Among Patients with Thalassemia in the 21st Century: a Report From the Thalassemia Clinical Research Network (TCRN) Longitudinal Cohort.. *Blood*, **2009**, 114, 4056-4056 | 2.2 | 4 |
| 217 | Arginine Therapy for Vaso-Occlusive Pain Episodes in Sickle Cell Disease.. *Blood*, **2009**, 114, 573-573 | 2.2 | 4 |
| 216 | Iron Overload Diminishes the Effectiveness of the Innate Immune Response in Thalassemia Major: a Possible Mechanism for Increased Infection Risk.. *Blood*, **2009**, 114, 4071-4071 | 2.2 | |
| 215 | Heightened Sulfur Amino Acid Oxidation in Plasma and Erythrocytes in Thalassemia Major.. *Blood*, **2009**, 114, 4065-4065 | 2.2 | |
| 214 | Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. *Transfusion*, **2008**, 48, 1971-80 | 2.9 | 23 |
| 213 | Advances in clinical research in sickle cell disease. *British Journal of Haematology*, **2008**, 141, 346-56 | 4.5 | 35 |
| 212 | Pulmonary complications of sickle cell disease. *New England Journal of Medicine*, **2008**, 359, 2254-65 | 59.2 | 322 |
| 211 | Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. *Bone*, **2008**, 43, 162-168 | 4.7 | 49 |
| 210 | Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. *Haematologica*, **2008**, 93, 817-25 | 6.6 | 61 |
| 209 | Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial. *Acta Haematologica*, **2008**, 119, 133-41 | 2.7 | 54 |

| | | | |
|---|---|---|---|
| 208 | Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.]. *Hemoglobin*, **2008**, 32, 601-7 | 0.6 | 7 |
| 207 | Detection and assessment of stroke in patients with sickle cell disease: neuropsychological functioning and magnetic resonance imaging. *Pediatric Hematology and Oncology*, **2008**, 25, 409-21 | 1.7 | 33 |
| 206 | Oral iron chelators and the treatment of iron overload in pediatric patients with chronic anemia. *Pediatrics*, **2008**, 121, 1253-6 | 7.4 | 15 |
| 205 | Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. *Haematologica*, **2008**, 93, 1247-51 | 6.6 | 40 |
| 204 | Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. *British Journal of Haematology*, **2008**, 140, 104-12 | 4.5 | 36 |
| 203 | Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. *European Journal of Haematology*, **2008**, 80, 168-76 | 3.8 | 183 |
| 202 | Psychosocial and behavioral outcomes in children with sickle cell disease and their healthy siblings. *Journal of Behavioral Medicine*, **2008**, 31, 506-16 | 3.6 | 13 |
| 201 | Transfusional iron burden and liver toxicity after bone marrow transplantation for acute myelogenous leukemia and hemoglobinopathies. *Pediatric Blood and Cancer*, **2008**, 50, 319-24 | 3 | 33 |
| 200 | Clinical application of deferasirox: practical patient management. *American Journal of Hematology*, **2008**, 83, 398-402 | 7.1 | 98 |
| 199 | Hydroxycarbamide-induced changes in E/beta thalassemia red blood cells. *American Journal of Hematology*, **2008**, 83, 842-5 | 7.1 | 15 |
| 198 | Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. *Blood*, **2008**, 111, 402-10 | 2.2 | 128 |
| 197 | Deferasirox (Exjade ), the Once-Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5-Year Follow-up.. *Blood*, **2008**, 112, 1420-1420 | 2.2 | 8 |
| 196 | Hemoglobin H-Constant Spring in North America: A Common Alpha Thalassemia with Frequent Complications.. *Blood*, **2008**, 112, 1880-1880 | 2.2 | |
| 195 | Prolonged QTc in Sickle Cell Disease: A Potential Risk Factor for Early Death?. *Blood*, **2008**, 112, 2476-2476 | 2.2 | |
| 194 | Body Composition and Its Relationship to Growth and Bone Mass in Patients with Thalassemia. *Blood*, **2008**, 112, 3890-3890 | 2.2 | |
| 193 | Increased Nucleosomal DNA Fragmentation in Leukocytes of Thalassemia Patients.. *Blood*, **2008**, 112, 1868-1868 | 2.2 | |
| 192 | Iron homeostasis during transfusional iron overload in beta-thalassemia and sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression. *Pediatric Hematology and Oncology*, **2007**, 24, 237-43 | 1.7 | 28 |
| 191 | Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. *American Journal of Hematology*, **2007**, 82, 255-65 | 7.1 | 128 |

| | | | |
|---|---|---|---|
| 190 | Caregiving time in sickle cell disease: psychological effects in maternal caregivers. *Pediatric Blood and Cancer*, **2007**, 48, 64-71 | 3 | 37 |
| 189 | Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. *Pediatric Blood and Cancer*, **2007**, 49, 329-32 | 3 | 110 |
| 188 | A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. *British Journal of Haematology*, **2007**, 136, 501-8 | 4.5 | 233 |
| 187 | Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator. *British Journal of Haematology*, **2007**, 138, 374-81 | 4.5 | 34 |
| 186 | Hemoglobin e syndromes. *Hematology American Society of Hematology Education Program*, **2007**, 2007, 79-83 | 3.1 | 96 |
| 185 | Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. *Clinical Therapeutics*, **2007**, 29, 909-917 | 3.5 | 112 |
| 184 | Long-Term Efficacy and Safety with Deferasirox (Exjade , ICL670), a Once-Daily Oral Iron Chelator, in Pediatric Patients.. *Blood*, **2007**, 110, 2774-2774 | 2.2 | 4 |
| 183 | Long-Term Treatment with Deferasirox (Exjade , ICL670), a Once-Daily Oral Iron Chelator, Is Effective in Patients with Transfusion-Dependent Anemias.. *Blood*, **2007**, 110, 2777-2777 | 2.2 | 6 |
| 182 | Long-Term Efficacy and Safety of Deferasirox (Exjade , ICL670), a Once-Daily Oral Iron Chelator, in Patients with Sickle Cell Disease (SCD).. *Blood*, **2007**, 110, 3395-3395 | 2.2 | 5 |
| 181 | Candidate Gene Polymorphisms and Their Association with TCD Velocities in Children with Sickle Cell Disease.. *Blood*, **2007**, 110, 429-429 | 2.2 | 7 |
| 180 | Pulmonary Hypertension in Thalassemia: Association with Hemolysis, Arginine Metabolism Dysregulation, and a Hypercoagulable State. *Advances in Pulmonary Hypertension*, **2007**, 6, 31-38 | 0.5 | 8 |
| 179 | Neuropsychological (NP) Dysfunction and Neuroimaging Abnormalities in Neurologically Intact Adult Patients with Sickle Cell Disease (SCD).. *Blood*, **2007**, 110, 428-428 | 2.2 | |
| 178 | High Frequency of Asthma, Sepsis and Acute Chest Syndrome in Children with Sickle Cell Disease and Pulmonary Hypertension.. *Blood*, **2007**, 110, 3782-3782 | 2.2 | |
| 177 | Leukocyte Apoptosis and Mitochondrial Dysfunction in Thalassemia Patients Treated with Deferasirox or Deferoxamine.. *Blood*, **2007**, 110, 2773-2773 | 2.2 | |
| 176 | Dose-escalation study of ICA-17043 in patients with sickle cell disease. *Pharmacotherapy*, **2006**, 26, 1557-68 | 3.4 | 43 |
| 175 | Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state. *American Journal of Hematology*, **2006**, 81, 670-5 | 7.1 | 122 |
| 174 | Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment. *Journal of Bone and Joint Surgery - Series A*, **2006**, 88, 2573-82 | 5.6 | 65 |
| 173 | Prevalence of HFE mutations in California newborns. *Pediatric Hematology and Oncology*, **2006**, 23, 507-16 | 1.7 | 8 |

| | | | |
|---|---|---|---|
| 172 | Bone mineral density in children with sickle cell anemia. *Pediatric Blood and Cancer*, **2006**, 47, 901-6 | 3 | 53 |
| 171 | Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. *British Journal of Haematology*, **2006**, 135, 254-63 | 4.5 | 229 |
| 170 | Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. *British Journal of Haematology*, **2006**, 135, 574-82 | 4.5 | 148 |
| 169 | Collaborative Data Project [C-DATA] of the Comprehensive Sickle Cell Centers Program.. *Blood*, **2006**, 108, 1200-1200 | 2.2 | 4 |
| 168 | Oral Arginine Increases Erythrocyte Glutathione Levels in Sickle Cell Disease: Implications for Pulmonary Hypertension.. *Blood*, **2006**, 108, 1208-1208 | 2.2 | 1 |
| 167 | Leukocyte Apoptosis and Inflammation in Iron-Overloaded Patients with Sickle Cell Disease or Thalassemia: A Mechanism for Increased Stroke and Disease Severity in Sickle Cell Disease.. *Blood*, **2006**, 108, 1233-1233 | 2.2 | 1 |
| 166 | MRI Assessment of Pituitary Iron and Volume in Thalassemia, and Relation to Hypothalamic-Pituitary-Gonadal Axis Function (HPG): A Feasibility Study.. *Blood*, **2006**, 108, 1778-1778 | 2.2 | 1 |
| 165 | Safety and Efficacy of Peginterferon Alfa-2a and Ribavirin for Hepatitis C in Thalassemia.. *Blood*, **2006**, 108, 558-558 | 2.2 | 3 |
| 164 | Using qualitative and quantitative strategies to evaluate knowledge and perceptions about sickle cell disease and sickle cell trait. *Journal of the National Medical Association*, **2006**, 98, 704-10 | 2.3 | 50 |
| 163 | PHYSICAL THERAPY ALONE COMPARED WITH CORE DECOMPRESSION AND PHYSICAL THERAPY FOR FEMORAL HEAD OSTEONECROSIS IN SICKLE CELL DISEASE. *Journal of Bone and Joint Surgery - Series A*, **2006**, 88, 2573-2582 | 5.6 | 39 |
| 162 | Do Transfusions of Packed Red Blood Cells Decrease Renal Function in Adult Sickle Cell Patients?.. *Blood*, **2006**, 108, 3793-3793 | 2.2 | |
| 161 | Liver Iron Measurement by SQUID Compared to Liver Biopsy.. *Blood*, **2006**, 108, 3826-3826 | 2.2 | 0 |
| 160 | Left Ventricular Dysfunction in Chronically Transused Patients with Sickle Cell Anemia and Thalassemia.. *Blood*, **2006**, 108, 3745-3745 | 2.2 | |
| 159 | Iron Overload in Acute Myelogenous Leukemia after Bone Marrow Transplantation.. *Blood*, **2006**, 108, 5336-5336 | 2.2 | |
| 158 | Erythrocyte Glutathione Depletion Is Associated with Severity of Anemia and Pulmonary Hypertension in Patients with Sickle Cell Disease.. *Blood*, **2006**, 108, 788-788 | 2.2 | 1 |
| 157 | Bone Mineral Density in Transfusion Independent Thalassemia Patients.. *Blood*, **2006**, 108, 3353-3353 | 2.2 | |
| 156 | Bone and joint disease in sickle cell disease. *Hematology/Oncology Clinics of North America*, **2005**, 19, 929-41, viii | 3.1 | 35 |
| 155 | Changes in the epidemiology of thalassemia in North America: a new minority disease. *Pediatrics*, **2005**, 116, e818-25 | 7.4 | 87 |

| | | | |
|---|---|---|---|
| 154 | Clinical evaluation of avascular necrosis in patients with sickle cell disease: Children's Hospital Oakland Hip Evaluation Scale--a modification of the Harris Hip Score. *Archives of Physical Medicine and Rehabilitation*, **2005**, 86, 1369-75 | 2.8 | 29 |
| 153 | Changing patterns of thalassemia worldwide. *Annals of the New York Academy of Sciences*, **2005**, 1054, 18-24 | 6.5 | 144 |
| 152 | Hemoglobin E-beta-thalassemia: Progress report from the International Study Group. *Annals of the New York Academy of Sciences*, **2005**, 1054, 33-9 | 6.5 | 16 |
| 151 | Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment. *Annals of the New York Academy of Sciences*, **2005**, 1054, 250-6 | 6.5 | 14 |
| 150 | Treatment of hepatitis C virus infection in thalassemia. *Annals of the New York Academy of Sciences*, **2005**, 1054, 290-9 | 6.5 | 18 |
| 149 | Measuring chromosome breaks in patients with thalassemia. *Annals of the New York Academy of Sciences*, **2005**, 1054, 439-44 | 6.5 | 13 |
| 148 | Hemolysis-associated pulmonary hypertension in thalassemia. *Annals of the New York Academy of Sciences*, **2005**, 1054, 481-5 | 6.5 | 90 |
| 147 | Quality of life in patients with thalassemia intermedia compared to thalassemia major. *Annals of the New York Academy of Sciences*, **2005**, 1054, 457-61 | 6.5 | 62 |
| 146 | Outcomes of preimplantation genetic diagnosis therapy in treatment of beta-thalassemia: A retrospective analysis. *Annals of the New York Academy of Sciences*, **2005**, 1054, 500-3 | 6.5 | 18 |
| 145 | Utility of Holter electrocardiogram in iron-overloaded hemoglobinopathies. *Annals of the New York Academy of Sciences*, **2005**, 1054, 476-80 | 6.5 | 16 |
| 144 | A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia. *Annals of the New York Academy of Sciences*, **2005**, 1054, 486-91 | 6.5 | 13 |
| 143 | Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome. *British Journal of Haematology*, **2005**, 131, 378-88 | 4.5 | 54 |
| 142 | Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. *American Journal of Hematology*, **2005**, 80, 70-4 | 7.1 | 110 |
| 141 | Can peak systolic velocities be used for prediction of stroke in sickle cell anemia?. *Pediatric Radiology*, **2005**, 35, 66-72 | 2.8 | 32 |
| 140 | Barriers to adherence of deferoxamine usage in sickle cell disease. *Pediatric Blood and Cancer*, **2005** , 44, 500-7 | 3 | 41 |
| 139 | Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis. *American Journal of Clinical Pathology*, **2005**, 123, 146-52 | 1.9 | 46 |
| 138 | Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. *JAMA - Journal of the American Medical Association*, **2005**, 294, 81-90 | 27.4 | 522 |
| 137 | Abnormal Pulmonary Function in Adults and Children with Sickle Cell Disease.. *Blood*, **2005**, 106, 2319-2325 | 11.9 | 1 |

| | | | |
|---|---|---|---|
| 136 | Control of Oxidant-Stress and Inflammation by Iron Chelators Deferasirox (ICL670) or Deferoxamine in Thalassemia: An Ancillary Study of the Novartis CICL670A0107 Trial.. *Blood*, **2005**, 106, 3598-3598 | 2.2 | 2 |
| 135 | Increased Chromosomal Breaks in Sickle Cell Disease as Evidenced by the Presence of Micronuclei in Erythrocytes.. *Blood*, **2005**, 106, 3807-3807 | 2.2 | |
| 134 | Hospitalization Rate and Regional Differences in Comprehensive Care in Transfused Patients with Sickle Cell Disease Compared to Thalassemia: A Report from the Multi-Center Study of Iron Overload.. *Blood*, **2005**, 106, 3189-3189 | 2.2 | |
| 133 | Dysregulated Arginine Metabolism and Elevated Arginase Activity in Thalassemia.. *Blood*, **2005**, 106, 3644-3644 | 2.2 | |
| 132 | High Prevalence of Fractures and Bone Pain in Thalassemia: The Thalassemia Clinical Research Network Experience.. *Blood*, **2005**, 106, 2706-2706 | 2.2 | |
| 131 | Serum Ferritin and Liver Iron Concentration in Patients with Iron Overload.. *Blood*, **2005**, 106, 3833-3833 | 2.2 | |
| 130 | Quality of Life (QOL) in Sickle Cell Disease (SCD).. *Blood*, **2005**, 106, 1324-1324 | 2.2 | |
| 129 | Thalassemia. *Hematology American Society of Hematology Education Program*, **2004**, 2004, 14-34 | 3.1 | 165 |
| 128 | Pulmonary hypertension in sickle cell disease. *New England Journal of Medicine*, **2004**, 350, 857-9 | 59.2 | 83 |
| 127 | Hematologic problems in immigrants from Southeast Asia. *Hematology/Oncology Clinics of North America*, **2004**, 18, 1405-22, x | 3.1 | 11 |
| 126 | The role of fetal hemoglobin-enhancing agents in thalassemia. *Seminars in Hematology*, **2004**, 41, 17-22 | 4 | 18 |
| 125 | Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. *Blood*, **2004**, 103, 3689-94 | 2.2 | 134 |
| 124 | Gene interactions and stroke risk in children with sickle cell anemia. *Blood*, **2004**, 103, 2391-6 | 2.2 | 145 |
| 123 | Pulmonary Hypertension in Sickle Cell Disease: A Common Complication for Both Adults and Children.. *Blood*, **2004**, 104, 1666-1666 | 2.2 | 1 |
| 122 | Progression of Organ Dysfunction in Iron Overloaded Patients with Thalassemia and Sickle Cell Disease.. *Blood*, **2004**, 104, 1683-1683 | 2.2 | 1 |
| 121 | Progression of Avascular Necrosis of the Hip in Sickle Cell Disease: 2 Year Follow-Up of Randomized Trial of Aggressive Physical Therapy and Hip Coring Decompression.. *Blood*, **2004**, 104, 1685-1685 | 2.2 | 1 |
| 120 | The Arginine-to-Ornithine Ratio: Biomarker of Arginase Activity and Predictor of Mortality in Sickle Cell Disease.. *Blood*, **2004**, 104, 237-237 | 2.2 | 3 |
| 119 | An Effective Program to Resolve Ambiguous Results from State Newborn Hemoglobinopathy Screening.. *Blood*, **2004**, 104, 3563-3563 | 2.2 | 1 |

| | | | |
|---|---|---|---|
| 118 | Biotin-Labeled RBC Survival in Thalassemia and Impact of Treatment.. *Blood*, **2004**, 104, 3616-3616 | 2.2 | 0 |
| 117 | Barriers to Deferoxamine Adherence for Adults with Sickle Cell Disease.. *Blood*, **2004**, 104, 3760-3760 | 2.2 | 2 |
| 116 | Assessing Compliance to Iron Chelation Therapy in Patients with Thalassemia.. *Blood*, **2004**, 104, 3787-3787 | 2.2 | 2 |
| 115 | Serum Ferritin a Predictor of Iron Overload in Patients with Thalassemia and Sickle Cell Disease?.. *Blood*, **2004**, 104, 3789-3789 | 2.2 | 2 |
| 114 | Low Bone Mass in Thalassemia: The Thalassemia Clinical Research Network (TCRN) Experience.. *Blood*, **2004**, 104, 3613-3613 | 2.2 | |
| 113 | Pulmonary Hypertension: A Common Complication in Thalassemia.. *Blood*, **2004**, 104, 3612-3612 | 2.2 | |
| 112 | Toxic Unbound Iron and Membrane Injury in b-Thalassemia and Sickle Cell Disease: Elevated Non-Transferrin Bound Iron (NTBI) and Malondialdehyde (MDA).. *Blood*, **2004**, 104, 3608-3608 | 2.2 | |
| 111 | Quality of Life in Patients with Thalassemia.. *Blood*, **2004**, 104, 3786-3786 | 2.2 | |
| 110 | Utility of Holter Electrocardiogram Monitoring in Iron over Loaded Thalassemia and Sickle Cell Disease.. *Blood*, **2004**, 104, 3784-3784 | 2.2 | |
| 109 | The Outcomes of Preimplantation Genetic Diagnosis Therapy in Treatment of Thalassemia - a Retrospective Analysis.. *Blood*, **2004**, 104, 3783-3783 | 2.2 | |
| 108 | Pulmonary Hypertension in Thalassemia: Association with Platelet Activation and Hypercoagulable State.. *Blood*, **2004**, 104, 3618-3618 | 2.2 | |
| 107 | Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?. *American Journal of Respiratory and Critical Care Medicine*, **2003**, 168, 63-9 | 10.2 | 258 |
| 106 | Chlamydia pneumoniae and acute chest syndrome in patients with sickle cell disease. *Journal of Pediatric Hematology/Oncology*, **2003**, 25, 46-55 | 1.2 | 44 |
| 105 | Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease. *Journal of Pediatric Hematology/Oncology*, **2003**, 25, 629-34 | 1.2 | 68 |
| 104 | Distinct HLA associations by stroke subtype in children with sickle cell anemia. *Blood*, **2003**, 101, 2865-9 | 2.2 | 63 |
| 103 | Deferiprone and hepatic fibrosis. *Blood*, **2003**, 101, 5089-90; author reply 5090-1 | 2.2 | 13 |
| 102 | Mycoplasma disease and acute chest syndrome in sickle cell disease. *Pediatrics*, **2003**, 112, 87-95 | 7.4 | 58 |
| 101 | Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. *Journal of Pediatrics*, **2003**, 143, 438-44 | 3.6 | 111 |

| | | | |
|---|---|---|---|
| 100 | Liver Ferritin Subunit Ratios in Neonatal Hemochromatosis. *Pediatric Hematology and Oncology*, **2003**, 20, 229-235 | 1.7 | 8 |
| 99 | Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. *JAMA - Journal of the American Medical Association*, **2003**, 289, 1645-51 | 27.4 | 592 |
| 98 | Managing sickle cell disease. *BMJ, The*, **2003**, 327, 1151-5 | 5.9 | 110 |
| 97 | Assessment of sickle cell pain in children and young adults using the adolescent pediatric pain tool. *Journal of Pain and Symptom Management*, **2002**, 23, 114-20 | 4.8 | 50 |
| 96 | Central venous catheter complications in sickle cell disease. *American Journal of Hematology*, **2002**, 69, 103-8 | 7.1 | 57 |
| 95 | Using quality improvement strategies to enhance pediatric pain assessment. *International Journal for Quality in Health Care*, **2002**, 14, 39-47 | 1.9 | 85 |
| 94 | Pancytopenia induced by hypothermia. *Journal of Pediatric Hematology/Oncology*, **2002**, 24, 681-4 | 1.2 | 14 |
| 93 | Longitudinal changes in ferritin during chronic transfusion: a report from the Stroke Prevention Trial in Sickle Cell Anemia (STOP). *Journal of Pediatric Hematology/Oncology*, **2002**, 24, 284-90 | 1.2 | 42 |
| 92 | Novel therapeutic approaches in sickle cell disease. *Hematology American Society of Hematology Education Program*, **2002**, 2002, 10-34 | 3.1 | 8 |
| 91 | Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. *Blood*, **2002**, 99, 3014-8 | 2.2 | 273 |
| 90 | New therapies in sickle cell disease. *Lancet, The*, **2002**, 360, 629-31 | 40 | 53 |
| 89 | Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. *Journal of Pediatrics*, **2002**, 140, 225-9 | 3.6 | 68 |
| 88 | Diseases of iron metabolism. *Pediatric Clinics of North America*, **2002**, 49, 893-909 | 3.6 | 12 |
| 87 | Correlation of abnormal intracranial vessel velocity, measured by transcranial Doppler ultrasonography, with abnormal conjunctival vessel velocity, measured by computer-assisted intravital microscopy, in sickle cell disease. *Blood*, **2001**, 97, 3401-4 | 2.2 | 31 |
| 86 | A novel multilocus genotyping assay to identify genetic predictors of stroke in sickle cell anaemia. *British Journal of Haematology*, **2001**, 114, 718-20 | 4.5 | 21 |
| 85 | Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. *Transfusion*, **2001**, 41, 1086-92 | 2.9 | 252 |
| 84 | Stem Cell Transplantation for Sickle Cell Disease: Can We Reduce the Toxicity?. *Fetal and Pediatric Pathology*, **2001**, 20, 73-86 | | 4 |
| 83 | Universal newborn screening for Hb H disease in California. *Genetic Testing and Molecular Biomarkers*, **2001**, 5, 93-100 | | 76 |

| | | | |
|---|---|---|---|
| 82 | Neuropsychologic performance in school-aged children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease. *Journal of Pediatrics*, **2001**, 139, 391-7 | 3.6 | 203 |
| 81 | Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. *Journal of Pediatrics*, **2001**, 139, 385-90 | 3.6 | 229 |
| 80 | Consensus document for transfusion-related iron overload. *Seminars in Hematology*, **2001**, 38, 2-4 | 4 | 32 |
| 79 | Current issues with blood transfusions in sickle cell disease. *Seminars in Hematology*, **2001**, 38, 14-22 | 4 | 101 |
| 78 | Current issues with blood transfusions in sickle cell disease. *Seminars in Hematology*, **2001**, 38, 14-22 | 4 | 90 |
| 77 | Transfusion therapy: a coming-of-age treatment for patients with sickle cell disease. *The American Journal of Pediatric Hematology/oncology*, **2001**, 23, 197-202 | | 13 |
| 76 | Outreach strategies for Southeast Asian communities: experience, practice, and suggestions for approaching Southeast Asian immigrant and refugee communities to provide thalassemia education and trait testing. *The American Journal of Pediatric Hematology/oncology*, **2000**, 22, 588-92 | | 14 |
| 75 | Changing outcome of homozygous alpha-thalassemia: cautious optimism. *The American Journal of Pediatric Hematology/oncology*, **2000**, 22, 539-42 | | 53 |
| 74 | Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. *The American Journal of Pediatric Hematology/oncology*, **2000**, 22, 515-20 | | 142 |
| 73 | Report of Proceedings: 1999 International Conference on E-Thalassemia. *The American Journal of Pediatric Hematology/oncology*, **2000**, 22, 550 | | 6 |
| 72 | Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. *British Journal of Haematology*, **2000**, 111, 498-500 | 4.5 | 4 |
| 71 | Acute Chest Syndrome in Sickle Cell Disease: Pathophysiology and Management. *Journal of Intensive Care Medicine*, **2000**, 15, 159-166 | 3.3 | 5 |
| 70 | Evidence for HLA-related susceptibility for stroke in children with sickle cell disease. *Blood*, **2000**, 95, 3562-3567 | 2.2 | 54 |
| 69 | Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. *Blood*, **2000**, 96, 76-79 | 2.2 | 162 |
| 68 | Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. *Blood*, **2000**, 96, 3369-3373 | 2.2 | 200 |
| 67 | Secretory phospholipase A2 predicts impending acute chest syndrome in sickle cell disease. *Blood*, **2000**, 96, 3276-3278 | 2.2 | 80 |
| 66 | Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. *New England Journal of Medicine*, **2000**, 342, 1855-65 | 59.2 | 857 |
| 65 | Sickle-cell disease not identified by newborn screening because of prior transfusion. *Journal of Pediatrics*, **2000**, 136, 248-50 | 3.6 | 20 |

| | | | |
|---|---|---|---|
| 64 | Acute Chest Syndrome in Sickle Cell Disease: Pathophysiology and Management. *Journal of Intensive Care Medicine*, **2000**, 15, 159-166 | 3.3 | 3 |
| 63 | Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. *Blood*, **2000**, 96, 76-79 | 2.2 | 8 |
| 62 | Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. *Blood*, **2000**, 96, 3369-3373 | 2.2 | 15 |
| 61 | Evidence for HLA-related susceptibility for stroke in children with sickle cell disease. *Blood*, **2000**, 95, 3562-3567 | 2.2 | |
| 60 | Secretory phospholipase A2 predicts impending acute chest syndrome in sickle cell disease. *Blood*, **2000**, 96, 3276-3278 | 2.2 | 2 |
| 59 | Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. *British Journal of Haematology*, **2000**, 111, 498-500 | 4.5 | 95 |
| 58 | Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease. *The American Journal of Pediatric Hematology/oncology*, **2000**, 22, 330-4 | | 34 |
| 57 | Multicenter comparison of magnetic resonance imaging and transcranial Doppler ultrasonography in the evaluation of the central nervous system in children with sickle cell disease. *The American Journal of Pediatric Hematology/oncology*, **2000**, 22, 335-9 | | 72 |
| 56 | Clinician assessment for acute chest syndrome in febrile patients with sickle cell disease: is it accurate enough?. *Annals of Emergency Medicine*, **1999**, 34, 64-9 | 2.1 | 45 |
| 55 | Erythrocytapheresis for chronically transfused children with sickle cell disease: an effective method for maintaining a low hemoglobin S level and reducing iron overload. *Journal of Clinical Apheresis*, **1999**, 14, 122-5 | 3.2 | 65 |
| 54 | Deferoxamine treatment during pregnancy: is it harmful?. *American Journal of Hematology*, **1999**, 60, 24-6 | 7.1 | 43 |
| 53 | The perioperative complication rate of orthopedic surgery in sickle cell disease: report of the National Sickle Cell Surgery Study Group. *American Journal of Hematology*, **1999**, 62, 129-38 | 7.1 | 101 |
| 52 | Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia. *American Journal of Hematology*, **1999**, 62, 221-7 | 7.1 | 45 |
| 51 | Bone disease in beta-thalassaemia. *Lancet, The*, **1999**, 354, 881-2 | 40 | 11 |
| 50 | Tonsillectomy, adenoidectomy, and myringotomy in sickle cell disease: perioperative morbidity. Preoperative Transfusion in Sickle Cell Disease Study Group. *Journal of Pediatric Hematology/Oncology*, **1999**, 21, 129-35 | 1.2 | 37 |
| 49 | Effects of red blood cell transfusion on resting energy expenditure in adolescents with sickle cell anemia. *Journal of Pediatric Gastroenterology and Nutrition*, **1999**, 29, 127-31 | 2.8 | 10 |
| 48 | Transfusion practice for patients with sickle cell disease. *Current Opinion in Hematology*, **1999**, 6, 432-6 | 3.3 | 11 |
| 47 | The perioperative complication rate of orthopedic surgery in sickle cell disease: Report of the national sickle cell surgery study group **1999**, 62, 129 | | 3 |

| | | | |
|---|---|---|---|
| 46 | Erythrocytapheresis for chronically transfused children with sickle cell disease: An effective method for maintaining a low hemoglobin S level and reducing iron overload **1999**, 14, 122 | | 3 |
| 45 | Preliminary report: hydroxyurea produces significant clinical response in thalassemia intermedia. *Annals of the New York Academy of Sciences*, **1998**, 850, 461-2 | 6.5 | 9 |
| 44 | The social impact of migration on disease. Cooley's anemia, thalassemia, and new Asian immigrants. *Annals of the New York Academy of Sciences*, **1998**, 850, 509-11 | 6.5 | 12 |
| 43 | Stroke prevention trial in sickle cell anemia. *Contemporary Clinical Trials*, **1998**, 19, 110-29 | | 187 |
| 42 | Surgery in patients with hemoglobin SC disease. Preoperative Transfusion in Sickle Cell Disease Study Group. *American Journal of Hematology*, **1998**, 57, 101-8 | 7.1 | 52 |
| 41 | Correction of the anemia of epidermolysis bullosa with intravenous iron and erythropoietin. *Journal of Pediatrics*, **1998**, 132, 871-3 | 3.6 | 22 |
| 40 | Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. *New England Journal of Medicine*, **1998**, 339, 5-11 | 59.2 | 1462 |
| 39 | The natural history of sickle cell disease. *Current Opinion in Pediatrics*, **1998**, 10, 49-52 | 3.2 | 21 |
| 38 | Hydroxyurea in children with sickle cell disease: impact on splenic function and compliance with therapy. *Journal of Pediatric Hematology/Oncology*, **1998**, 20, 26-31 | 1.2 | 51 |
| 37 | Acute chest syndrome and sickle cell disease. *Current Opinion in Hematology*, **1998**, 5, 89-92 | 3.3 | 20 |
| 36 | New therapies and approaches to transfusion in sickle cell disease in children. *Current Opinion in Pediatrics*, **1997**, 9, 41-5 | 3.2 | 6 |
| 35 | Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. *American Journal of Medicine*, **1997**, 102, 171-7 | 2.4 | 194 |
| 34 | Umbilical cord blood stem cells: application for the treatment of patients with hemoglobinopathies. *Journal of Pediatrics*, **1997**, 130, 695-703 | 3.6 | 32 |
| 33 | Acute Chest Syndrome in Sickle Cell Disease: Clinical Presentation and Course. *Blood*, **1997**, 89, 1787-1792 | 2.2 | 420 |
| 32 | Decrease of Very Late Activation Antigen-4 and CD36 on Reticulocytes in Sickle Cell Patients Treated With Hydroxyurea. *Blood*, **1997**, 89, 2554-2559 | 2.2 | 125 |
| 31 | Acute Chest Syndrome in Sickle Cell Disease: Clinical Presentation and Course. *Blood*, **1997**, 89, 1787-1792 | 2.2 | 15 |
| 30 | Influence of penicillin prophylaxis on antimicrobial resistance in nasopharyngeal S. pneumoniae among children with sickle cell anemia. The Ancillary Nasopharyngeal Culture Study of Prophylactic Penicillin Study II. *The American Journal of Pediatric Hematology/oncology*, **1997**, 19, 327-33 | | 21 |
| 29 | Pulmonary complications. *Hematology/Oncology Clinics of North America*, **1996**, 10, 1275-87 | 3.1 | 20 |

| | | | |
|---|---|---|---|
| 28 | Serotype-specific immunoglobulin G antibody responses to pneumococcal polysaccharide vaccine in children with sickle cell anemia: effects of continued penicillin prophylaxis. *Journal of Pediatrics*, **1996**, 129, 828-35 | 3.6 | 38 |
| 27 | Ototoxicity in hemoglobinopathy patients chelated with desferrioxamine. *Journal of Pediatric Hematology/Oncology*, **1996**, 18, 42-5 | 1.2 | 14 |
| 26 | Newborn screening for sickle cell disease: 4 years of experience from California's newborn screening program. *Journal of Pediatric Hematology/Oncology*, **1996**, 18, 36-41 | 1.2 | 60 |
| 25 | Core decompression in avascular necrosis of the hip in sickle-cell disease. *American Journal of Hematology*, **1996**, 52, 103-7 | 7.1 | 61 |
| 24 | Core decompression in avascular necrosis of the hip in sickle-cell disease **1996**, 52, 103 | | 4 |
| 23 | Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. *Journal of Pediatrics*, **1995**, 127, 685-90 | 3.6 | 166 |
| 22 | Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. *Journal of Pediatrics*, **1995**, 126, 896-9 | 3.6 | 299 |
| 21 | Liver transplantation in a child with sickle cell anemia. *Transplantation*, **1995**, 59, 1490-2 | 1.8 | 23 |
| 20 | Effects of a long-term transfusion regimen on sickle cell-related illnesses. *Journal of Pediatrics*, **1994**, 125, 909-11 | 3.6 | 74 |
| 19 | Universal screening for hemoglobinopathies using high-performance liquid chromatography: clinical results of 2.2 million screens. *European Journal of Human Genetics*, **1994**, 2, 262-71 | 5.3 | 39 |
| 18 | A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. *New England Journal of Medicine*, **1993**, 328, 81-6 | 59.2 | 397 |
| 17 | Sickle cell disease in a patient with sickle cell trait and compound heterozygosity for hemoglobin S and hemoglobin Quebec-Chori. *New England Journal of Medicine*, **1991**, 325, 1150-4 | 59.2 | 51 |
| 16 | Pain in sickle cell disease. Rates and risk factors. *New England Journal of Medicine*, **1991**, 325, 11-6 | 59.2 | 1212 |
| 15 | Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. *New England Journal of Medicine*, **1990**, 322, 1617-21 | 59.2 | 447 |
| 14 | Vitamin C deficiency in patients with sickle cell anemia. *Journal of Pediatric Hematology/Oncology*, **1990**, 12, 262-7 | 1.2 | 23 |
| 13 | The Role of Oxidation in Diseases of the Human Erythrocyte **1990**, 34-47 | | |
| 12 | Contraceptive use in the chronically ill adolescent female. *Journal of Adolescent Health Care: Official Publication of the Society for Adolescent Medicine*, **1988**, 9, 87 | | |
| 11 | Suggested Guidelines for the Treatment of Children with Sickle Cell Anemia. *Hematology/Oncology Clinics of North America*, **1987**, 1, 483-501 | 3.1 | 19 |

| | | | |
|---|---|---|---|
| 10 | Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. *New England Journal of Medicine*, **1986**, 314, 1593-9 | 59.2 | 877 |
| 9 | Growth retardation in sickle-cell disease treated by nutritional support. *Lancet, The*, **1985**, 1, 903-6 | 40 | 61 |
| 8 | Inadequate erythroid response to hypoxia in cystic fibrosis. *Journal of Pediatrics*, **1984**, 105, 15-21 | 3.6 | 24 |
| 7 | Concurrent sickle-cell anemia and alpha-thalassemia: effect on severity of anemia. *New England Journal of Medicine*, **1982**, 306, 270-4 | 59.2 | 218 |
| 6 | Peroxidation, vitamin E, and sickle-cell anemia. *Annals of the New York Academy of Sciences*, **1982**, 393, 323-35 | 6.5 | 48 |
| 5 | Sickle cell anemia and related hemoglobinopathies. *Pediatric Clinics of North America*, **1980**, 27, 429-47 | 3.6 | 49 |
| 4 | Unstable hemoglobins, hemoglobins with altered oxygen affinity, and m-hemoglobins. *Pediatric Clinics of North America*, **1980**, 27, 421-8 | 3.6 | 1 |
| 3 | Current treatment of sickle cell disease. *Current Problems in Pediatrics*, **1980**, 10, 1-64 | | 4 |
| 2 | Anemia associated with rheumatoid arthritis. *Journal of Pediatrics*, **1979**, 94, 678 | 3.6 | 3 |
| 1 | Anemia in the Newborn Period. *Pediatric Annals*, **1979**, 8, 10-37 | 1.3 | 3 |